AndroGel Benefits Not Worth Cardiac Risk, Jury Hears
A man suing AbbVie Inc. over its testosterone replacement therapy, AndroGel, told an Illinois federal jury Monday that the benefits he received from using the gel did not outweigh its risk...To view the full article, register now.
Already a subscriber? Click here to view full article